C4 Therapeutics officer proposes $122K share sale

Available on EDGAR 11/12/2026 - 04:23 PM EST Accepted by SEC EDGAR 11/12/2026 - 04:23 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

C4 Therapeutics, Inc. officer Kendra Adams reported a proposed sale of 45,173 common shares, with an aggregate market value of $122,486.59 and an approximate sale date of November 12, 2026. The shares were acquired upon vesting of restricted stock and Performance Shares from May 26, 2022 through February 14, 2026. The reported Rule 10b5-1 plan-adoption or instruction date is August 13, 2026; Morgan Stanley Smith Barney LLC is named as broker.

Key Figures

Common shares proposed for sale: 45,173 shares Aggregate market value: $122,486.59 Common shares outstanding: 131,317,488 shares

3 metrics

Common shares proposed for sale 45,173 shares Kendra Adams's proposed sale

Aggregate market value $122,486.59 Proposed sale of 45,173 common shares

Common shares outstanding 131,317,488 shares C4 Therapeutics, Inc.

Key Terms

Rule 10b5-1, restricted stock, Performance Shares

3 terms

Rule 10b5-1 regulatory

"Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

restricted stock technical

"vesting of restricted stock and Performance Shares"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Performance Shares technical

"vesting of restricted stock and Performance Shares"

Performance shares are a type of company stock given to executives or employees that only become theirs if the company meets specific goals, like hitting certain profits or growth targets. They motivate leaders to work toward the company’s success, because their additional shares depend on achieving these results.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CCCC shares is Kendra Adams proposing to sell?

Kendra Adams, an officer of C4 Therapeutics, reported a proposed sale of 45,173 common shares, with an aggregate market value of $122,486.59. The approximate sale date is November 12, 2026.

Which broker is listed for Kendra Adams's CCCC share sale?

Morgan Stanley Smith Barney LLC is named as broker for the proposed sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001991929
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	C4 THERAPEUTICS, INC.
SEC File Number	001-39567
Address of Issuer	490 Arsenal Way, Suite 120 Watertown MASSACHUSETTS 02472
Phone	(617) 231-0700
Name of Person for Whose Account the Securities are To Be Sold	KENDRA ADAMS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	45173	122486.59	131317488	11/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/26/2022	Performance and Restricted Stock	ISSUER			45173	05/26/2022	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock and Performance Shares during the period of 5/26/2022 through 2/14/2026
Date of Notice	11/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kendra Adams
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)